Now is the time to address the Culture of Residential Aged Care Facilities to support Pharmacists in reducing psychotropic prescribing

Mouna Sawan (Corresponding Author), Timothy Chen, Phyo Kyaw Myint, Yun-Hee Jeon, Sarah Hilmer

Research output: Contribution to journalEditorial

Abstract

The high‐level use of psychotropic medicines, particularly antipsychotics, for the treatment of behavioural and psychological symptoms of dementia (BPSD) in residential aged care facilities (RACFs) is widely reported. The current estimates of the prevalence of psychotropic medicines in such facilities are high: 44% in the UK,1 61% in Australia2 and over 60% in the United States.3 Psychotropic medicines are recommended not to be used first‐line for the management of BPSD, and among residents with dementia are associated with significant adverse outcomes.3, 4 However, the use of these medicines remains high. They are often used outside of approved indications, for longer than recommended or at higher doses.
Original languageEnglish
Pages (from-to)404-405
Number of pages2
JournalInternational Journal of Pharmacy Practice
Volume27
Issue number5
Early online date6 Sep 2019
DOIs
Publication statusE-pub ahead of print - 6 Sep 2019

Fingerprint

Pharmacists
Medicine
Dementia
Behavioral Symptoms
Psychology
Antipsychotic Agents
Therapeutics
UK 1

Cite this

Now is the time to address the Culture of Residential Aged Care Facilities to support Pharmacists in reducing psychotropic prescribing. / Sawan, Mouna (Corresponding Author); Chen, Timothy; Myint, Phyo Kyaw; Jeon, Yun-Hee; Hilmer, Sarah.

In: International Journal of Pharmacy Practice, Vol. 27, No. 5, 10.2019, p. 404-405.

Research output: Contribution to journalEditorial

@article{badeac3afc154cbca1bd18b7a16014ab,
title = "Now is the time to address the Culture of Residential Aged Care Facilities to support Pharmacists in reducing psychotropic prescribing",
abstract = "The high‐level use of psychotropic medicines, particularly antipsychotics, for the treatment of behavioural and psychological symptoms of dementia (BPSD) in residential aged care facilities (RACFs) is widely reported. The current estimates of the prevalence of psychotropic medicines in such facilities are high: 44{\%} in the UK,1 61{\%} in Australia2 and over 60{\%} in the United States.3 Psychotropic medicines are recommended not to be used first‐line for the management of BPSD, and among residents with dementia are associated with significant adverse outcomes.3, 4 However, the use of these medicines remains high. They are often used outside of approved indications, for longer than recommended or at higher doses.",
author = "Mouna Sawan and Timothy Chen and Myint, {Phyo Kyaw} and Yun-Hee Jeon and Sarah Hilmer",
year = "2019",
month = "9",
day = "6",
doi = "10.1111/ijpp.12501",
language = "English",
volume = "27",
pages = "404--405",
journal = "International Journal of Pharmacy Practice",
issn = "0961-7671",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - Now is the time to address the Culture of Residential Aged Care Facilities to support Pharmacists in reducing psychotropic prescribing

AU - Sawan, Mouna

AU - Chen, Timothy

AU - Myint, Phyo Kyaw

AU - Jeon, Yun-Hee

AU - Hilmer, Sarah

PY - 2019/9/6

Y1 - 2019/9/6

N2 - The high‐level use of psychotropic medicines, particularly antipsychotics, for the treatment of behavioural and psychological symptoms of dementia (BPSD) in residential aged care facilities (RACFs) is widely reported. The current estimates of the prevalence of psychotropic medicines in such facilities are high: 44% in the UK,1 61% in Australia2 and over 60% in the United States.3 Psychotropic medicines are recommended not to be used first‐line for the management of BPSD, and among residents with dementia are associated with significant adverse outcomes.3, 4 However, the use of these medicines remains high. They are often used outside of approved indications, for longer than recommended or at higher doses.

AB - The high‐level use of psychotropic medicines, particularly antipsychotics, for the treatment of behavioural and psychological symptoms of dementia (BPSD) in residential aged care facilities (RACFs) is widely reported. The current estimates of the prevalence of psychotropic medicines in such facilities are high: 44% in the UK,1 61% in Australia2 and over 60% in the United States.3 Psychotropic medicines are recommended not to be used first‐line for the management of BPSD, and among residents with dementia are associated with significant adverse outcomes.3, 4 However, the use of these medicines remains high. They are often used outside of approved indications, for longer than recommended or at higher doses.

U2 - 10.1111/ijpp.12501

DO - 10.1111/ijpp.12501

M3 - Editorial

VL - 27

SP - 404

EP - 405

JO - International Journal of Pharmacy Practice

JF - International Journal of Pharmacy Practice

SN - 0961-7671

IS - 5

ER -